- miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington's disease
- Fluid and Imaging Biomarkers in Huntington's Disease
- Imaging the glymphatic system in Huntington's disease: The benefits of a multimodal approach and clinical implications
- Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington's disease progression
- Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington's disease
- Nanotechnological and in vivo characterization of a new generation of brain-permeable nanoparticles for brain-targeted cholesterol delivery in Huntington's disease
- Unawareness of motor deficit in Huntington's disease
- L-theanine from Camellia sinensis (L.) attenuates 3-NP-induced Huntington's disease-like alterations by remedying behavioral patterns and modulating neurotransmitters across three distinct brain regions: evidence from in-vivo and in-silico approaches
- Early reduction of myelin-associated glycoprotein at myelin membranes in Huntington's disease
- The pathophysiology of depression in Huntington's disease
- Geometric properties of caudate and putamen mark the progression of Huntington's disease
- Network-based stratification of allele-specific expression reveals patient subgroups in Huntington's disease
- Dysfunction of Primary Cilium in Huntington's Disease: How Mutant Huntingtin Disrupts This Cellular Signaling Hub
- The Role of MicroRNA in Diagnosis of Huntington's Disease: A Systematic Review
- The potential of vitamins in Huntington's disease: bridging mechanistic evidence with translational limitations and future strategies
